Cost-effectiveness of anti-TNFalfa treatment for IBD

Cost-effectiveness of anti-TNFalfa treatment for IBD - Cost-effectiveness of anti-TNFalfa treatment for IBD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011358

Enrollment

350

Registered

2013-12-01

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with inflammatory bowel disease

Exclusion criteria

Exclusion criteria: severe heart failure severe kidny disease severe infection severe diabetes severe hypovolemic or nutrirional disorder other severe complications under 16-years-old

Design outcomes

Primary

Measure	Time frame
To determine the incremental cost-effectiveness ratio of anti-TNFalfa treatment in IBD patients	—

Secondary

Measure	Time frame
To determine the relationship between disease activity and QOL in IBD patients	—

Countries

Japan

Contacts

Public ContactTatsuya Dokoshi

Asahikawa Medical University Department of Medicine

ta1983@asahikawa-med.ac.jp0166-68-2462

Outcome results